WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation

Reuters01-15

WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation

WuXi AppTec Co. Ltd. has released a presentation outlining its performance and business strategy across its core Contract Research, Development & Manufacturing Organization (CRDMO) segments. The presentation highlights WuXi AppTec’s expansion of its small molecule pipeline, with 2,889 preclinical and Phase I molecules, 374 in Phase II, and 87 in Phase III as of Q3 2025. The company reports that 16% of global clinical stage new drugs are supported by its pipeline. Additionally, WuXi AppTec achieved an adjusted non-IFRS net profit of RMB 15.0 billion in 2025, with a net profit margin of 32.9%. The company continues to invest in enhancing global capabilities and expanding its footprint in regions such as Boston, New Jersey, Delaware, Munich, Couvet, Changshu, and Wuxi. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WuXi AppTec Co. Ltd. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603506623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603506623","market":"fut","top_or_hot":-1,"title":"WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WuXi AppTec Co. Ltd. has released a presentation outlining its performance and business strategy across its core Contract Research, Development &amp; Manufacturing Organization (CRDMO) segments. The presentation highlights WuXi AppTec’s expansion of its small molecule pipeline, with 2,889 preclinical and Phase I molecules, 374 in Phase II, and 87 in Phase III as of Q3 2025. The company reports that 16% of global clinical stage new drugs are supported by its pipeline. Additionally, WuXi AppTec achieved an adjusted non-IFRS net profit of RMB 15.0 billion in 2025, with a net profit margin of 32.9%. The company continues to invest in enhancing global capabilities and expanding its footprint in regions such as Boston, <a href=\"https://laohu8.com/S/NJR\">New Jersey</a>, <a href=\"https://laohu8.com/S/VMM\">Delaware</a>, Munich, Couvet, Changshu, and Wuxi. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WuXi AppTec Co. Ltd. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 08:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WuXi AppTec Co. Ltd. has released a presentation outlining its performance and business strategy across its core Contract Research, Development &amp; Manufacturing Organization (CRDMO) segments. The presentation highlights WuXi AppTec’s expansion of its small molecule pipeline, with 2,889 preclinical and Phase I molecules, 374 in Phase II, and 87 in Phase III as of Q3 2025. The company reports that 16% of global clinical stage new drugs are supported by its pipeline. Additionally, WuXi AppTec achieved an adjusted non-IFRS net profit of RMB 15.0 billion in 2025, with a net profit margin of 32.9%. The company continues to invest in enhancing global capabilities and expanding its footprint in regions such as Boston, <a href=\"https://laohu8.com/S/NJR\">New Jersey</a>, <a href=\"https://laohu8.com/S/VMM\">Delaware</a>, Munich, Couvet, Changshu, and Wuxi. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WuXi AppTec Co. Ltd. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL2vhs63:1","article_id":"2603506623","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603506623","pubTimestamp":1768435591,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"WuXi AppTec Co. Ltd. has released a presentation outlining its performance and business strategy across its core Contract Research, Development & Manufacturing Organization  segments. The presentation highlights WuXi AppTec’s expansion of its small molecule pipeline, with 2,889 preclinical and Phase I molecules, 374 in Phase II, and 87 in Phase III as of Q3 2025. The company reports that 16% of global clinical stage new drugs are supported by its pipeline. Additionally, WuXi AppTec achieved an adjusted non-IFRS net profit of RMB 15.0 billion in 2025, with a net profit margin of 32.9%. The company continues to invest in enhancing global capabilities and expanding its footprint in regions such as Boston, New Jersey, Delaware, Munich, Couvet, Changshu, and Wuxi. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0216":"研究试验","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU1997245094.SGD":"安联神州A股基金AT Acc SGD"},"translate_title":"药明康德在最新演示中强调全球CRDMO增长和创新平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9},"content_text":"WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation\n    \n\n        WuXi AppTec Co. Ltd. has released a presentation outlining its performance and business strategy across its core Contract Research, Development & Manufacturing Organization (CRDMO) segments. The presentation highlights WuXi AppTec’s expansion of its small molecule pipeline, with 2,889 preclinical and Phase I molecules, 374 in Phase II, and 87 in Phase III as of Q3 2025. The company reports that 16% of global clinical stage new drugs are supported by its pipeline. Additionally, WuXi AppTec achieved an adjusted non-IFRS net profit of RMB 15.0 billion in 2025, with a net profit margin of 32.9%. The company continues to invest in enhancing global capabilities and expanding its footprint in regions such as Boston, New Jersey, Delaware, Munich, Couvet, Changshu, and Wuxi. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WuXi AppTec Co. Ltd. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603506623","isCrawlerRequest":true}